Non-oxidative metabolism. No data pointing to CYP-interaction.

(To be edited, initial data ST OCT 04) Pyrrolidone derivative used in additional treatment of partial epileptic attacks.The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Does not interact with CYPs. See: Paul and Meencke. Levitiracetam in focal epilepsia and hepatic porphyria: a case report. Epilepsia 2004; 45: 559-60 ( No exacerbation noed)

Uneventful use reported in 6 patients with acute porphyria.